Literature DB >> 3280015

Inhibition of phosphatase and sulfatase by transition-state analogues.

P J Stankiewicz1, M J Gresser.   

Abstract

The inhibition constants for vanadate, chromate, molybdate, and tungstate have been determined with Escherichia coli alkaline phosphatase, potato acid phosphatase, and Helix pomatia aryl sulfatase. Vanadate was a potent inhibitor of all three enzymes. Inhibition of both phosphatases followed the order WO4(2-) greater than MoO4(2-) greater than CrO4(2-). The Ki values for potato acid phosphatase were about 3 orders of magnitude lower than those for alkaline phosphatase. Aryl sulfatase followed the reverse order of inhibition by group VI oxyanions. Phenol enhanced inhibition of alkaline phosphatase by vanadate and chromate but did not affect inhibition of acid phosphatase. Phenol enhanced inhibition of aryl sulfatase by metal oxyanions in all cases following the order H2VO4- greater than CrO4(2-) greater than MoO4(2-) greater than WO4(2-), and N-acetyltyrosine ethyl ester enhanced inhibition of aryl sulfatase by H2VO4- and CrO4(2-) more strongly than did phenol. It is apparent that the effectiveness of metal oxyanions as inhibitors of phosphatases and sulfatases can be selectively enhanced in the presence of other solutes. The relevance of these observations to the effects of transition metal oxyanions on protein phosphatases in vivo is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280015     DOI: 10.1021/bi00401a031

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Legionella pneumophila major acid phosphatase and its role in intracellular infection.

Authors:  V Aragon; S Kurtz; N P Cianciotto
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Reactive-oxygen-species-mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate, and molybdate in the PC-3 human prostate cancer cell line.

Authors:  Tong-Tong Liu; Yan-Jun Liu; Qin Wang; Xiao-Gai Yang; Kui Wang
Journal:  J Biol Inorg Chem       Date:  2011-10-20       Impact factor: 3.358

3.  Metavanadate at the active site of the phosphatase VHZ.

Authors:  Vyacheslav I Kuznetsov; Anastassia N Alexandrova; Alvan C Hengge
Journal:  J Am Chem Soc       Date:  2012-08-22       Impact factor: 15.419

4.  Improved peak capacity for CE separations of enzyme inhibitors with activity-based detection using magnetic bead microreactors.

Authors:  Xiaoyan Yan; S Douglass Gilman
Journal:  Electrophoresis       Date:  2010-01       Impact factor: 3.535

5.  Possible involvement of a tyrosine kinase-dependent pathway in the regulation of phosphoinositide metabolism by vanadate in normal mouse islets.

Authors:  J C Jonas; J C Henquin
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

6.  Vanadate-based transition-state analog inhibitors of Cre-LoxP recombination.

Authors:  Shelley S Martin; Shinichiro Wachi; Enoch P Baldwin
Journal:  Biochem Biophys Res Commun       Date:  2003-08-29       Impact factor: 3.575

7.  Aluminofluorides and beryllofluorides as inhibitors of sulphatases. Analogues of hydrogen sulphate?

Authors:  A B Roy
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

8.  Tungstate as a Transition State Analog for Catalysis by Alkaline Phosphatase.

Authors:  Ariana Peck; Fanny Sunden; Logan D Andrews; Vijay S Pande; Daniel Herschlag
Journal:  J Mol Biol       Date:  2016-05-14       Impact factor: 5.469

9.  Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstate.

Authors:  J Fernández-Alvarez; A Barberà; B Nadal; S Barceló-Batllori; S Piquer; M Claret; J J Guinovart; R Gomis
Journal:  Diabetologia       Date:  2004-02-14       Impact factor: 10.122

10.  Molecular mechanisms of tungstate-induced pancreatic plasticity: a transcriptomics approach.

Authors:  Jordi Altirriba; Albert Barbera; Héctor Del Zotto; Belen Nadal; Sandra Piquer; Alex Sánchez-Pla; Juan J Gagliardino; Ramon Gomis
Journal:  BMC Genomics       Date:  2009-08-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.